Axel Wester.
Photo: Göran Ekeberg
Scientific Frontline: Extended "At a Glance" Summary: Blood-Thinning Medications and Liver Cirrhosis Complications
The Core Concept: A nationwide registry study indicates that patients with liver cirrhosis and atrial fibrillation who take blood-thinning medications have a lower risk of developing severe liver-related complications, such as decompensated cirrhosis.
Key Distinction/Mechanism: Unlike previous concerns that blood thinners might exacerbate bleeding in cirrhosis patients, this observational study found that treatment was associated with a reduced risk of complications (specifically ascites, or fluid accumulation in the abdomen) without increasing the risk of major bleeding events.
Major Frameworks/Components:
- Study Design: An observational registry study comparing 383 treated patients against 777 untreated patients.
- Clinical Outcomes: The primary reduction in risk was observed for decompensated cirrhosis (10.4 percent of treated patients versus 16.6 percent of untreated patients).
- Safety Profile: Major bleeding occurred in 19.0 percent of treated patients compared to 19.8 percent of untreated patients, showing no increased risk of fatal, intracranial, or gastrointestinal bleeding.
- Requirement for Validation: As an observational study, it cannot establish definitive causality; randomized clinical trials are required to confirm these findings.
Branch of Science: Hepatology, Cardiology, Pharmacology.
Future Application: These findings provide a rationale for conducting randomized clinical trials, which could lead to revised clinical guidelines for safely managing atrial fibrillation in patients with compensated liver cirrhosis.
Why It Matters: The findings challenge the traditional caution against using blood thinners in patients with liver cirrhosis, suggesting that these medications can safely prevent stroke while concurrently reducing the risk of severe liver disease progression.
Patients with liver cirrhosis and atrial fibrillation who were treated with blood-thinning medications had a lower risk of developing severe liver-related complications. This is shown in a nationwide registry study from Karolinska Institutet published in the journal Clinical and Molecular Hepatology. The findings also suggest that the treatment is not associated with an increased risk of major bleeding.
Liver cirrhosis is a condition in which the liver becomes scarred and damaged. Due to the liver’s considerable reserve capacity, the disease is often initially compensated and symptom-free. As the condition progresses, patients may develop what is known as decompensated cirrhosis, which involves complications such as fluid accumulation in the abdomen, gastrointestinal bleeding, and liver failure. At the same time, many patients with cirrhosis also have atrial fibrillation, a heart rhythm disorder that is often treated with blood-thinning medications to prevent stroke. Researchers have long debated whether these medicines may also influence the course of liver cirrhosis.
In the current study, researchers analyzed data from 1,160 patients with compensated liver cirrhosis and newly diagnosed atrial fibrillation, identified through Swedish national health registers. Of these, 383 started treatment with a blood-thinning medication, while 777 did not. The researchers followed the patients for up to five years and compared the risk of liver-related complications and major bleeding.
Lower Risk of Severe Complications
After five years, 10.4% of patients who had started treatment had developed decompensated cirrhosis, compared with 16.6% of those who were not treated. The reduction in risk was seen primarily for fluid accumulation in the abdomen, known as ascites.
“Our findings suggest that blood-thinning medications used in the treatment of atrial fibrillation may be associated with a lower risk of severe complications in liver cirrhosis, without an increased risk of major bleeding,” says Axel Wester, physician and researcher at the Department of Medicine, Huddinge, Karolinska Institutet, and first author of the study.
An important question was whether the treatment increased the risk of major bleeding, something that has long contributed to caution when treating patients with cirrhosis. After five years, 19.0% of treated patients had experienced a major bleeding event, compared with 19.8% of those who did not receive treatment. The researchers also found no clear differences in fatal bleeding, intracranial bleeding, or gastrointestinal bleeding.
The study is observational, meaning that the researchers did not randomly assign patients to receive treatment or no treatment. As a result, it is not possible to establish a causal relationship with certainty.
“Randomized clinical trials are needed to determine conclusively whether treatment with blood-thinning medications actually reduces the risk of decompensated cirrhosis. However, our findings support the rationale for conducting such studies,” says Axel Wester.
Funding: Funding was provided, among others, by the Swedish Gastrointestinal Foundation, the Professor Nanna Svartz Foundation, Region Stockholm, the Swedish Society of Medicine, Forte, the Swedish Research Council, and the Swedish Cancer Society. The researchers report certain institutional research grants and consultancy assignments unrelated to the present study.
Published in journal: Clinical and Molecular Hepatology
Authors: Axel Wester, Emilie Toresson Grip, Rupesh Rajani, Anthony A. Matthews, Hannes Hagström, and Ying Shang
Source/Credit: Karolinska Institutet
Edited by: Scientific Frontline
Reference Number: med092826_01
